ALSO NOTED: Wockhardt gets OK for Zithromax copy; Depomed's gabapentin formula passes Phase II;

> Wockhardt got the FDA nod to sell a copycat form of Pfizer's Zithromax, an antibiotic. Report

> Depomed announced that its in-development extended release form of gabapentin showed efficacy against menopausal hot flashes in a Phase II trial. Report

> Nektar Therapeutics' COO Dr. Hoyoung Huh stepped down to take a CEO job at BiPar Sciences; separately, the company said it would cut 150 employees, or about 20 percent of its workforce. Release | Release

> A new study found that the epilepsy med Trileptal didn't prevent migraines; the drug and its ilk have been used against migraine for decades. Report

> An Alabama attorney asked a jury to award the state $40 million in compensatory damages in a fraud lawsuit against AstraZeneca, which alleges that the company inflated its prices. Report

> The FDA has told Adolor and GSK that it will take three more months to review Entereg, a anti-constipation drug candidate. Report

> Italy's Newron Pharmaceuticals has U.K.-based Hunter-Fleming, a company that's developing therapies for neurodegenerative and inflammatory disorders. Report

> An article in the Indianapolis Star details Lilly's development program for MBP9289, a multiple sclerosis drug offering hope to both patients and a drug developer that hasn't launched a new drug for humans since 2005. Report

> Rumors are swirling that Sanofi-Aventis may be making a bid for Oxford BioMedica, a U.K.-based developer of gene-based medicines. Report

And Finally... Just in time for Valentine's Day, more good news about chocolate's health effects. Report

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.